Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Robin Kate Kelley, Bruno Sangro, William Harris, Masafumi Ikeda, Takuji Okusaka, Yoon Koo Kang, Shukui Qin, David W.M. Tai, Ho Yeong Lim, Thomas Yau, Wei Peng Yong, Ann Lii Cheng, Antonio Gasbarrini, Silvia Damian, Jordi Bruix, Mitesh Borad, Johanna Bendell, Tae You Kim, Nathan Standifer, Philip HeMallory Makowsky, Alejandra Negro, Masatoshi Kudo, Ghassan K. Abou-Alfa

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study'. Together they form a unique fingerprint.

Medicine & Life Sciences